Genitourinary chlamydial infection: A reappraisal and hypothesis

International Journal of STD and AIDS

Volumn 10, Issue 12, 1999, Pages 765-775

  Morton, R S ^a,c   Kinghorn, G R ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Chlamydia trachomatis; Immune responses; Latency; Pathogenesis; Treatment

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; METRONIDAZOLE; PENICILLIN G; RIFAMPICIN; ROXITHROMYCIN; TETRACYCLINE;

CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; FEMALE; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOPATHOLOGY; MALE; MEDICAL RESEARCH; MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; UROGENITAL TRACT INFECTION;

CARRIER STATE; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; RECURRENCE;

EID: 0032752955     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462991913448     Document Type: Review

References (89)

1. 1 Harkness AH. Non-gonococcal Urethritis. Edinburgh: E & S Livingstone, 1950
2. 2 Dunlop EMC, Jones BR, Khalof Al-Hussaini M. Genital infections in association with Tric virus infection of the eye. Br J Vener Dis 1964;40:33-42
3. 3 Dean D, Ferrero U, McCarthy M. Comparison of performance and cost-effectiveness of direct fluorescent antibody, ligase chain reaction and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of Chlamydia trachomatis infection. J Clin Microbiol 1998;36:94-9
4. 4 Stary A, Schuh E, Kerschbaumer M, Gotz B, Lee H. Performance of transcription-mediated amplification and ligase chain reaction assays for detection of chlamydial infection in urogenital samples obtained by invasive and noninvnsive methods. J Clin Microbiol 1998;36:2666-70
5. 5 Bowie W. Urethritis, Prostatitis, Epididymitis. World Health Organization Group on Non-gonococcal urethritis. Report TNT/VDT. 78, 348. Geneva: WHO, 1978
6. 6 Morton RS, Kinghorn CR. Non-gonococcal urethritis; unanswered questions. Proc R Coll Physicians (Edinb) 1993; 23:641-1
7. 7 Beatty WL, Bryne GI, Morrison RP. Repeated and persistent infections with chlamydia and the development of chronic inflammation and ulcers. Trend Microbiol 1994;2:94-8
8. 8 Ward ME. Immunobiology and immunopathology of chlamydial infections. APMIS (formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica) 1995;103: 769-96
9. 9 Clay JC, Bowman CA. Controlling chlamydial infection. Genitourin Med 1996;72:145
10. 10 Hafiz S, McEntegart MB, Morton RS, Waitkins SA. Clostridium difficite in the urogenital tract of males and females. Lancet 1975;347:420-1
11. 11 Igietseme JU, Iriri TM, Chow M, et al. Inhibition of intracellular multiplication of human strains of C. trachomatis. Biochem Biophys Res Commun 1997;232:595-601
12. 12 Bergsson G, Arnifinnsson J, Karlsson SM, Sleingrimmsson O, Thormar H. In vitro inactivation of Chlamydia trachomatis by fatty acids and monoglycerides. Antimicrob Agents Chemother 1998;42:2290-4
13. 13 Parkes KS, Dixon PB, Richey CM, Hook EW 3rd. Spontaneous clearance of C. trachomatis infections in untreated patients. Sex Transm Dis 1997;24:229-35
14. 14 Rasmussen SJ, Eckmann I, Quayle AJ, et al. Secretion of proinflammatory cytokines by epithelial cells in response to chlamydial infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997;99:77-87
15. 15 Shahmanesh M. Characteristics of inflammatory cells in urethral smears from men with non-gonococcal urethritis. Genitourin Med 1989;65:18-21
16. 16 Lampe MF, Wilson CB, Bevan MJ, Starnbach MN. Gamma interferon production by cytotoxic T lymphocytes is required for resolution of Chlamydia trachomatis infection. Infect Immun 1998;66:5457-61
17. 17 Bobo LD, Novak N, Munz B, et al. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis 1997;176:1524-30
18. 18 Morton RS, Read L. Non-gonococcal urethritis. Br J Vener Dis 1957;33:223-7
19. 19 Hurst EW, Peters JM, Melvin P. The therapy of experimental psittacosis and lymphogranuloma venereum. Br J Pharm Chemother 1950;5:611-24
20. 20 Hurst EW, Landquist JK, Melvin P, et al. The therapy of experimental psittacosis and lymphogranuloma venereum. Br J Pharm Chemother 1953;8:297-305
21. 21 Morton RS, Morrison AI. Penicillin in non-gonococcal urethritis. Br J Vener Dis 1963;39:244-5
22. 22 Bardin T, Enel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arth Rheum 1992;35:190-4
23. 23 Matzinger P. Danger and the extended family. Ann Rev Immunol 1994;12:991-1045
24. 24 Larkin M. Polly Matzinger, immunology's dangerous thinker. Lancet 1997;350:38
25. 25 Johansson M, Schon K, Ward M, Lycke N. Studies in knock out mice reveal that anti-chlamydial infection requires TH1 cells producing IFN-gamma. Is this true of humans? Scand J Immunol 1997;46:546-52
26. 26 Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from arteriosclerotic coronary arteries. Antimicrob Agents Chemother 1998;42:2762-4
27. 27 Kaufpinen MJ, Saikku P, Kujala P, et al. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydia and pneumococcal pneumonia. Thorax 1996;51:185-90
28. 28 Munday PE. Persistent and recurrent NGU. In: Taylor-Robinson D, ed. Clinical Problems in Sexually Transmitted Disease. Dordrecht: Martinus Nijhof, 1985:15-35
29. 29 Blythe MJ, Katz BP, Battergar BE, et al. Recurrent genitourinary chlamydial infections in sexually active female adolescents. J Pediatr 1992;121:487-93
30. 30 Hillis SD, Coles FB, Lichfield B, et al. Doxycycline and azithromycin for prevention of chlamydia persistence or recurrence one month after treatment of women. A use-effectiveness study in public health. Sex Transin Dia 1998;25:5-11
31. 31 Dhar J, Arya OP, Timmins DJ, et al. The efficacy of azithromycin versus doxycycline in the treatment of non-gonococcal urethritis (abstract). MSSVD Meeting, Dublin 1992
32. 32 Beatty WL, Morrison RP, Byrine GJ. Reactivation of persistent C. trachomatis infection in cell culture. Infect Immun 1995;63:199-205
33. 33 Bhattacharya MN, Morton RS. Long term triple tetracycline therapy in non-specific urethritis. Br J Vener Dis 1971;47:266-9
34. 34 Morton RS. A reappraisal of non-specific genital infection with reference to the work of the late Dr E Weston-Hurst. Br J Vener Dis 1983;59:394-6
35. 35 Morre SA, Sillekens PT, Jacobs MV, et al. Monitoring of Chlamydia trachomatis infections after antibiotic treatment using RNA detection by nucleic acid sequence based amplification. Molecular Pathol 1998;51:49-54
36. 36 Evans BA. The role of tetracyclines in the treatment of non-specific urethritis. Br J Vener Dis 1978;54:107-11
37. 37 Woolley PD, Kinghorn GR, Talbot MD, et al. Efficiency of combined metronidazole and triple tetracycline therapy in treatment of NGU. Int J Sex Transin Dis AIDS 1990;1:35-7
38. 38 Evans BA. The role of tetracyclines in the treatment of non-specific urethritis. Br J Vener Dis 1977;53:40-3
39. 39 Helmy N, Fowler W. Intensive and prolonged tetracycline therapy in non-specific urethritis. Br J Vener Dis 1975;51:336-9
40. 40 Rosedale N. Female consorts of men with NGU. Br J Vener Dis 1959;35:245-8
41. 41 Fitzgerald MR. Effect of epidemiological treatment of contacts in preventing recurrence of NGU. Br J Vener Dis 1984;60:312-15
42. 42 Woolley PD, Wilson JD, Kinghorn GR. Epidemiological treatment of sexual contacts prevents recurrence of NGU. Genitourin Med 1987;63:384-5
43. 43 Shahmanesh M, Pandit PG, Pound R. Urethral lymphocyte isolations in non-gonococcal urethritis. Genitourin Med 1996;72:362-4
44. 44 Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997;349:1068-73
45. 45 Atkins MI, Carlin EM, Emery VC, et al. Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases. BMJ 1996;313:341-2
46. 46 Morre SA, Ossewaarde JM, Lan J, et al. Serotyping and genotyping of genital Chlamydia trachomatis isolates reveals variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. J Clin Microbiol 1998;36:345-51
47. 47 van Duynhoven YT, Ossewaarde JM, Derksen-Nawrocki RP, van der Meijden WI, van de Laar MJ. Chlamydia trachomatis genotypes: correlation with clinical manifestations of infection and patients' characteristics. Clin Infect Dis 1998;26:214-22
48. 48 Morton RS. White cell counts in human semen: use in the diagnosis of prostatitis with reference to uveitis. Br J Vener Dis 1968;44:72-4
49. 49 Kreiger JN, Riley DE, Roberts MC, Bergen RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 1996;34:3120-8
50. 50 Gerard HC, Branigan PJ, Schumacher HR Jr, et al. Synovial C. trachomatis in patients with reactive Reiter's syndrome are viable but show aberrant gene expressions. J Rheumatol 1998;25:734-42
51. 51 Morrison RP. Persistent C. trachomatis infection: in vitro phenomenon or in vivo trigger of reactive arthritis? (Editorial). J Rheumatol 1998;25:610-12
52. 52 Leiberman D, Schoeffer F, Dolder I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one-year prospective study of 346 consecutive patients, Thorax 1996;51:179-84
53. 53 Muller-Schoob JW, Wana S-P, Murginge J, et al. C. trachomatis as possible cause of peritonitis, perihepatitis in young women. BMJ 1978;1:1022-4
54. 54 Eschenbach DA. Sexually Transmitted Diseases. New York: McCraw Hill, 1984:633-8
55. 55 Mabet UA, Stadler LA, Vogtlin J, et al. Diffuse peritonitis and chronic ascites due to infection with Chlamydia trachomatis in patients with liver disease; a new presentation of the Fitz-Hugh Curtis syndrome. BMJ 1986;293:5-6
56. 56 Shanahan D. Cloak and dagger - studies of chlamydial peritonitis in humans and mice. Paper read at meeting of the Medical Society for the Study of Venereal Disease, London, 30 November 1990
57. 57 Drake AJ, Morton RS. Acute anterior uveitis in men. Br J Ophthalmol 1968;52:907-9
58. 58 Paavonnen J, Lehtinen M. Chlamydial pelvic inflammatory disease (Review Ref: 104). Hum Reprod Update 1996;2:519-29
59. 59 Reiter H. Über eine bisher unerkannte Spirochäteninfektion. Dfsch Med Wschr 1916;42:1535-6
60. 60 Fiessinger N, Leroy E. Contribution à l'étude d'une épidémie de dysenterie dans la Somme (Juillet-Octobre 1916). Bull Soc Mid Hôp (Paris) 1916;40:2030-69
61. 61 Greenblatt KB. Management of Chancroid, Granuloma Inguinale and Lymphogranuloma Venereum. Washington: US Dept of Health Education and Welfare, 1953:38-48
62. 62 Johnson JD, Hand WL, Francis JB, et al. Antibiotic uptake by alveolar macrophages. J Lab Clin Med 1980;95:429-39
63. 63 Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. ] Infect Dis 1998;173:725-9
64. 64 Kalayoglu MV, Byrne GI. Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998;66:5067-72
65. 65 Mosca, Briceno L, 1 Hermandez MI. Cell mediated immunity in Chagas disease. Trypanosoma cruzi antigens induce suppression of the in vitro proliferative response of mononuclear cells. Memorias do Institutio Oswaldo Cruz 1991;85:147-52
66. 66 Dannenberg AM Jr. Roles of cytotoxic delayed type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Iniituiuobiol 1994;191:461-73
67. 67 Domeika M, Domeika K, Paavonnen J, Mardh PA, Witkin SS. Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60k-Da heat-shock proteins in women with pelvic inflammatory disease. J Infect Dis 1998;177:714-19
68. 68 Mendall MA, Carrington D, Strachan D, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995;30:121-8
69. 69 Saikku P, Matilla K, Nieminen MS, et al. Serological evidence of an association of a novel chlamydia TWAR with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:963-6
70. 70 Saikku P, Leinonen M, Tenkanen L, et al. Chronic C. pneumoniae disease in Helsinki Heart Study. Ann Intern Med 1992;116:273-8
71. 71 Juvonen J, Juvonen T, Laurila A, et al. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann Intern Med 1998;128:741-4
72. 72 Petersen E, Boman J, Persson K, et al. Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vascular Endovascular Surgery 1998;15:138-42
73. 73 Boman J, Soderberg S, Forsberg J, et al. High prevalence of C. pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998;178:274-7
74. 74 Gurfinkel E, Bosowich G, Dovoka A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes. ROXIS pilot study. Lancet 1997;350:404-7
75. 75 Stachan DP, Carrington D, Mendall MA, et al. Relation of C. pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in Caerphilly prospective heart disease study. BMJ 1999;318:1035-9
76. 76 Jackson LA, Nicholas LS, Hickbert SR, et al. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, and doxycycline. Emerg Infect Dis 1999;5:281-4
77. 77 Gupta S, Leathans EW, Carrington D, et al. Elevated C. pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infection. Circulation 1997;96:404-7
78. 78 Sinisalo J, Mattila K, Nieminen MS, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk, and forearm based nitric oxide production. J Antimicrob Chemother 1998;41:85-92
79. 79 Drebu YJ, Mehtar S, Blakemore PH. The in vitro activity of roxithromycin (RU28965) compared with four other antibiotics. Drugs Exp Clin Res 1987;13:201-3
80. 80 Chastre J, Brun P, Fourtillan J, et al. Pulmonary deposition of roxithromycin (RU28965), a new macrolide antibiotic. Antimicrob Agents Chemother 1987;31:1312-16
81. 81 Anderson R, von Rensburg C, Joone G, et al. An in vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J Antimicrob Chemother 1987;19:275-6
82. 82 Young RA, Gonzalez J, Sorkin E. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties, and clinical efficacy. Drugs 1989;37:69-71
83. 83 Ehrlich P, Morgenroth J. 'On haemolysins', Third and fifth communications. In: Collected Papers of Paul Ehrlich. London: Permagon, 1957:205-55
84. 84 Shahmanesh M. Problems with NGU. Int J Sex Transm Dis AIDS 1994;5:390-9
85. 85 Metters JA. Chlamydia trachomatis. Summary and conclusions of Chief Medical Officers' Expert Advisory Group, 1998
86. 86 Report 'In Brief'. BMJ 1998;317:1406
87. 87 Kudesia G, Zadik PM, Ripley M. Chlamydia trachomatis infection in males attending general practitioners. Genitourin Med 1994;70:356
88. 88 Chernesky M, Luinstra K, Sellars J, et al. Can serology diagnose upper genital tract C. trachomatis infection? Studies in women with pelvic pain with and without chlamydia plasmid DNA in endometrial biopsy tissue. Sex Transm Dis 1998;25:14-19
89. 89 Taylor-Robinson D. Chlamydia trachomatis and sexually transmitted disease. What do we know and what do we do? (Editorial). BMJ 1994;308:150-1